{"id":12479,"date":"2022-02-14T17:43:13","date_gmt":"2022-02-14T22:43:13","guid":{"rendered":"https:\/\/www.med.unc.edu\/neurology\/?p=12479"},"modified":"2023-11-17T14:37:36","modified_gmt":"2023-11-17T19:37:36","slug":"phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/","title":{"rendered":"Phase 3 study results show positive data in treatment of myasthenia gravis with zilucoplan"},"content":{"rendered":"<ul>\n<li>Positive topline results show the Phase 3 RAISE (NCT04115293) zilucoplan trial met primary and all key secondary endpoints in adults with generalized myasthenia gravis.<\/li>\n<li>The results show a favorable safety profile and good tolerability.<\/li>\n<li>UCB plans to proceed with zilucoplan regulatory submissions later this year.<\/li>\n<li>Results follow recent positive topline data from the Phase 3 MycarinG study investigating rozanolixizumab, a monoclonal antibody also being developed by UCB in the same indication.<\/li>\n<li>These results are the latest in a series of positive phase 3 data announcements by the company across its product pipeline.<\/li>\n<\/ul>\n<figure id=\"attachment_3020\" class=\"thumbnail wp-caption alignright\" style=\"width: 211px\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-3020\" src=\"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2018\/05\/fda-approves-eculizumab-for-generalized-myasthenia-gravis-image2.png\" alt=\"James F. Howard Jr., MD\" width=\"201\" height=\"152\" srcset=\"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2018\/05\/fda-approves-eculizumab-for-generalized-myasthenia-gravis-image2.png 201w, https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2018\/05\/fda-approves-eculizumab-for-generalized-myasthenia-gravis-image2-150x113.png 150w\" sizes=\"auto, (max-width: 201px) 100vw, 201px\" \/><figcaption class=\"caption wp-caption-text\">James F. Howard Jr., MD<\/figcaption><\/figure>\n<p>UCB, a global biopharmaceutical company, announced positive topline results from the RAISE (NCT04115293) trial\u00a0evaluating its investigational treatment zilucoplan, a self-administered, subcutaneous (SC) peptide inhibitor of complement component 5 (C5 inhibitor), versus placebo in adults with generalized myasthenia gravis (gMG).<\/p>\n<p>\u201cgMG patients can experience varying and debilitating symptoms that impact their everyday lives in unique ways,\u201d said James F. Howard, MD, Distinguished Professor of Neuromuscular Disease, Chief, Neuromuscular Disorders Section, University of North Carolina School of Medicine and lead investigator in the RAISE trial. \u201cThese exciting results give us additional reason to believe that zilucoplan can offer an important step forward in addressing the unmet needs of people living with gMG. As we strive to improve the management of this complex and unpredictable disease, any new medicines will be welcomed by physicians to help us realize our goal of offering effective and flexible treatment approaches in gMG which are tailored to the needs of individual patients.\u201d<\/p>\n<p>The primary endpoint of the trial was met; a clinically meaningful and statistically significant improvement from baseline in Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 12 was observed for the zilucoplan treatment group vs placebo.<\/p>\n<p>All key secondary endpoints were also met, including statistically significant improvements from baseline in Quantitative Myasthenia Gravis (QMG) score, Myasthenia Gravis Composite (MGC) score and MG-QoL15r score at Week 12 for the zilucoplan treatment group vs placebo.<\/p>\n<p>The results show zilucoplan was well-tolerated and no major unexpected safety findings were identified compared to earlier zilucoplan studies. The incidence of serious treatment emergent adverse events (TEAEs) in the zilucoplan and placebo treatment arms was similar.<\/p>\n<p>The safety and efficacy of zilucoplan have not been established, and it is not approved for use in any indication by any regulatory authority worldwide.<\/p>\n<p>Based on these results, UCB plans to progress with regulatory filings for zilucoplan in gMG in the United States (US), European Union (EU) and Japan, beginning later this year.<\/p>\n<p>These findings from RAISE build on the positive results from the Phase 3 MycarinG study evaluating UCB\u2019s investigational treatment rozanolixizumab, an SC-infused monoclonal antibody targeting the neonatal Fc receptor (FcRn) which also met its primary and secondary endpoints with statistical significance in gMG.<sup>2<\/sup><\/p>\n<p>UCB is currently the only company investigating two potential treatments with different mechanisms of action in gMG. Detailed results from both Phase 3 trials will be presented at forthcoming medical meetings in 2022.<\/p>\n<p>\u201cWhile there has been recent progress in the treatment of MG, there is still a significant unmet need for new, effective treatment options that address the unpredictable, fluctuating symptoms of MG \u2013 some of which require urgent treatment or hospitalization \u2013 to improve patient outcomes and quality of life,\u201d said Raquel Pardo, Spanish Myasthenia Association (AMES), Spain. \u201cNew research into additional treatment options will be welcomed by the global MG community.\u201d<\/p>\n<p>Iris Loew-Friedrich, Executive Vice-President and Chief Medical Officer added: \u201cThis is the latest in a series of positive Phase 3 data announcements across UCB\u2019s product pipeline validating our patient value strategy and laying foundations for future sustainable growth. Today\u2019s results represent another significant milestone in UCB\u2019s efforts to bring transformational outcomes to those living with myasthenia gravis. Positive results for zilucoplan and rozanolixizumab \u2013 each with a different mechanism of action \u2013 bring us one step closer to achieving our ambition of delivering choice and flexibility for a broad range of patients and physicians at each step of their treatment journey, addressing significant unmet needs and offering unique patient value. We thank the MG community for their continued insights, partnership and participation in this study.\u201d<\/p>\n<p><a href=\"https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-positive-data-in-myasthenia-gravis-with-zilucoplan-phase-3-study-results\">Learn more &gt;<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>James F. Howard Jr., MD, professor in the ºÚÁÏÍø Department of Neurology, was lead investigator in UCB&#8217;s RAISE trial to evaluate zilucoplan as a treatment for generalized myasthenia gravis in adults. <\/p>\n","protected":false},"author":58435,"featured_media":8494,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"layout":"","cellInformation":"","apiCallInformation":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[103,2,134],"tags":[],"class_list":["post-12479","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical-trial","category-news","category-research","odd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Phase 3 study results show positive data in treatment of myasthenia gravis with zilucoplan | Department of Neurology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phase 3 study results show positive data in treatment of myasthenia gravis with zilucoplan | Department of Neurology\" \/>\n<meta property=\"og:description\" content=\"James F. Howard Jr., MD, professor in the ºÚÁÏÍø Department of Neurology, was lead investigator in UCB&#039;s RAISE trial to evaluate zilucoplan as a treatment for generalized myasthenia gravis in adults.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/\" \/>\n<meta property=\"og:site_name\" content=\"Department of Neurology\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ºÚÁÏÍøNeurology\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-14T22:43:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-17T19:37:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"2560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Peggy Felix\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ºÚÁÏÍøneurology\" \/>\n<meta name=\"twitter:site\" content=\"@ºÚÁÏÍøneurology\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Peggy Felix\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/\"},\"author\":{\"name\":\"Peggy Felix\",\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/#\/schema\/person\/14c90ff7a3e23f1201695fd9f347c9fd\"},\"headline\":\"Phase 3 study results show positive data in treatment of myasthenia gravis with zilucoplan\",\"datePublished\":\"2022-02-14T22:43:13+00:00\",\"dateModified\":\"2023-11-17T19:37:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/\"},\"wordCount\":706,\"publisher\":{\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-scaled.jpg\",\"articleSection\":[\"Clinical Trial\",\"News\",\"Research\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/\",\"url\":\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/\",\"name\":\"Phase 3 study results show positive data in treatment of myasthenia gravis with zilucoplan | Department of Neurology\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-scaled.jpg\",\"datePublished\":\"2022-02-14T22:43:13+00:00\",\"dateModified\":\"2023-11-17T19:37:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#primaryimage\",\"url\":\"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-scaled.jpg\",\"contentUrl\":\"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-scaled.jpg\",\"width\":2048,\"height\":2560,\"caption\":\"James F. Howard, Jr., MD\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.med.unc.edu\/neurology\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Phase 3 study results show positive data in treatment of myasthenia gravis with zilucoplan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/#website\",\"url\":\"https:\/\/www.med.unc.edu\/neurology\/\",\"name\":\"Department of Neurology\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.med.unc.edu\/neurology\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/#organization\",\"name\":\"ºÚÁÏÍø Department of Neurology\",\"url\":\"https:\/\/www.med.unc.edu\/neurology\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2018\/05\/new_neurology_logo.jpg\",\"contentUrl\":\"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2018\/05\/new_neurology_logo.jpg\",\"width\":1657,\"height\":601,\"caption\":\"ºÚÁÏÍø Department of Neurology\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ºÚÁÏÍøNeurology\/\",\"https:\/\/x.com\/ºÚÁÏÍøneurology\",\"https:\/\/www.instagram.com\/unc_neurology\/\",\"https:\/\/www.linkedin.com\/in\/unc-neurology\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/#\/schema\/person\/14c90ff7a3e23f1201695fd9f347c9fd\",\"name\":\"Peggy Felix\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/neurology\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6969269aed21efffa0d42102c2dd1953?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6969269aed21efffa0d42102c2dd1953?s=96&d=mm&r=g\",\"caption\":\"Peggy Felix\"},\"description\":\"Neurosurgery - Admin\",\"url\":\"https:\/\/www.med.unc.edu\/neurology\/author\/pfelix\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Phase 3 study results show positive data in treatment of myasthenia gravis with zilucoplan | Department of Neurology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/","og_locale":"en_US","og_type":"article","og_title":"Phase 3 study results show positive data in treatment of myasthenia gravis with zilucoplan | Department of Neurology","og_description":"James F. Howard Jr., MD, professor in the ºÚÁÏÍø Department of Neurology, was lead investigator in UCB's RAISE trial to evaluate zilucoplan as a treatment for generalized myasthenia gravis in adults.","og_url":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/","og_site_name":"Department of Neurology","article_publisher":"https:\/\/www.facebook.com\/ºÚÁÏÍøNeurology\/","article_published_time":"2022-02-14T22:43:13+00:00","article_modified_time":"2023-11-17T19:37:36+00:00","og_image":[{"width":2048,"height":2560,"url":"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-scaled.jpg","type":"image\/jpeg"}],"author":"Peggy Felix","twitter_card":"summary_large_image","twitter_creator":"@ºÚÁÏÍøneurology","twitter_site":"@ºÚÁÏÍøneurology","twitter_misc":{"Written by":"Peggy Felix","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#article","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/"},"author":{"name":"Peggy Felix","@id":"https:\/\/www.med.unc.edu\/neurology\/#\/schema\/person\/14c90ff7a3e23f1201695fd9f347c9fd"},"headline":"Phase 3 study results show positive data in treatment of myasthenia gravis with zilucoplan","datePublished":"2022-02-14T22:43:13+00:00","dateModified":"2023-11-17T19:37:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/"},"wordCount":706,"publisher":{"@id":"https:\/\/www.med.unc.edu\/neurology\/#organization"},"image":{"@id":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-scaled.jpg","articleSection":["Clinical Trial","News","Research"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/","url":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/","name":"Phase 3 study results show positive data in treatment of myasthenia gravis with zilucoplan | Department of Neurology","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/neurology\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#primaryimage"},"image":{"@id":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-scaled.jpg","datePublished":"2022-02-14T22:43:13+00:00","dateModified":"2023-11-17T19:37:36+00:00","breadcrumb":{"@id":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#primaryimage","url":"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-scaled.jpg","contentUrl":"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-scaled.jpg","width":2048,"height":2560,"caption":"James F. Howard, Jr., MD"},{"@type":"BreadcrumbList","@id":"https:\/\/www.med.unc.edu\/neurology\/phase-3-study-results-show-positive-data-in-treatment-of-myasthenia-gravis-with-zilucoplan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.med.unc.edu\/neurology\/"},{"@type":"ListItem","position":2,"name":"Phase 3 study results show positive data in treatment of myasthenia gravis with zilucoplan"}]},{"@type":"WebSite","@id":"https:\/\/www.med.unc.edu\/neurology\/#website","url":"https:\/\/www.med.unc.edu\/neurology\/","name":"Department of Neurology","description":"","publisher":{"@id":"https:\/\/www.med.unc.edu\/neurology\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.med.unc.edu\/neurology\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.med.unc.edu\/neurology\/#organization","name":"ºÚÁÏÍø Department of Neurology","url":"https:\/\/www.med.unc.edu\/neurology\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/neurology\/#\/schema\/logo\/image\/","url":"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2018\/05\/new_neurology_logo.jpg","contentUrl":"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2018\/05\/new_neurology_logo.jpg","width":1657,"height":601,"caption":"ºÚÁÏÍø Department of Neurology"},"image":{"@id":"https:\/\/www.med.unc.edu\/neurology\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ºÚÁÏÍøNeurology\/","https:\/\/x.com\/ºÚÁÏÍøneurology","https:\/\/www.instagram.com\/unc_neurology\/","https:\/\/www.linkedin.com\/in\/unc-neurology\/"]},{"@type":"Person","@id":"https:\/\/www.med.unc.edu\/neurology\/#\/schema\/person\/14c90ff7a3e23f1201695fd9f347c9fd","name":"Peggy Felix","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/neurology\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6969269aed21efffa0d42102c2dd1953?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6969269aed21efffa0d42102c2dd1953?s=96&d=mm&r=g","caption":"Peggy Felix"},"description":"Neurosurgery - Admin","url":"https:\/\/www.med.unc.edu\/neurology\/author\/pfelix\/"}]}},"featured_image":"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-scaled.jpg","featured_image_medium":"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-240x300.jpg","featured_image_medium_large":"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-768x960.jpg","featured_image_large":"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-819x1024.jpg","featured_image_thumbnail":"https:\/\/www.med.unc.edu\/neurology\/wp-content\/uploads\/sites\/716\/2020\/05\/DSC_5379-150x150.jpg","featured_image_alt":"James F. Howard, Jr., MD","category_details":[{"name":"Clinical Trial","link":"https:\/\/www.med.unc.edu\/neurology\/category\/clinical-trial\/"},{"name":"News","link":"https:\/\/www.med.unc.edu\/neurology\/category\/news\/"},{"name":"Research","link":"https:\/\/www.med.unc.edu\/neurology\/category\/research\/"}],"tag_details":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/neurology\/wp-json\/wp\/v2\/posts\/12479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/neurology\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.unc.edu\/neurology\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/neurology\/wp-json\/wp\/v2\/users\/58435"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/neurology\/wp-json\/wp\/v2\/comments?post=12479"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/neurology\/wp-json\/wp\/v2\/posts\/12479\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/neurology\/wp-json\/wp\/v2\/media\/8494"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/neurology\/wp-json\/wp\/v2\/media?parent=12479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.unc.edu\/neurology\/wp-json\/wp\/v2\/categories?post=12479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.unc.edu\/neurology\/wp-json\/wp\/v2\/tags?post=12479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}